Copanlisib Tested in Relapsed/ Refractory Indolent Lymphoma (CME/CE)

(MedPage Today) -- Upregulated PI3K/BCR signaling associated with better outcomes in phase II study
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Lymphoma | Primary Care | Study